What's happening
This bill requires insurance plans to cover at least one abuse-deterrent opioid per active ingredient at the lowest cost-sharing level, prohibiting increased costs or barriers for patients and prescribers.
Why it matters
Reduces barriers for safer opioid prescriptions. By requiring coverage and prohibiting extra prior authorization steps for abuse-deterrent opioids, the bill makes it easier for doctors to prescribe, and patients to access, products designed to reduce misuse and addiction risk.
Limits patient out-of-pocket costs. The bill ensures that abuse-deterrent opioids are not more expensive for patients than standard opioids, potentially increasing their use and lowering financial obstacles for those needing pain management.
Targets insurance practices that may discourage abuse-deterrent options. Insurers cannot shift costs to patients or create disincentives for prescribers and pharmacies as a workaround, closing loopholes that might undermine the law’s intent.
Responds to the opioid crisis with a focus on prevention. By prioritizing access to abuse-deterrent formulations, the legislation addresses opioid misuse at the prescription level, aiming to prevent addiction and diversion before it starts.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Insurance carriers and health plans
The bill would require coverage of at least one abuse-deterrent opioid product per opioid analgesic active ingredient and prohibit requiring use of non-abuse-deterrent opioids first.
Patients prescribed opioid pain medications
The bill would cap cost-sharing for covered abuse-deterrent opioids at the lowest level for covered non-abuse-deterrent opioids in the corresponding brand or generic category.
Prescribers and pharmacists
The bill would prohibit insurers from using disincentives for prescribers or dispensers to comply with its coverage requirements.
Manufacturers of abuse-deterrent opioids
Products with FDA-approved abuse-deterrence labeling would qualify for the bill’s formulary coverage and cost-sharing protections.
Headline styles
Limit Opioid Substitution Rules
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to insurance
- Referred to insurance
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
6180
2021-2022 Regular Sessions
IN SENATE
April 13, 2021
Introduced by Sen. LANZA -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance
AN ACT to amend the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The insurance law is amended by adding a new section 3216-a to read as follows:
§ 3216-a. Access to abuse-deterrent opioid medications. (a) An insurance carrier or health plan shall provide coverage on its formulary, drug list or other lists of similar construct for at least one abusedeterrent opioid analgesic drug product per opioid analgesic active ingredient.
(1) Cost-sharing for brand name abuse-deterrent opioid analgesic drug products covered pursuant to this section shall not exceed the lowest cost-sharing level applied to brand name non-abuse deterrent opioid drugs covered under the applicable health plan or policy.
(2) Cost-sharing for generic abuse-deterrent opioid analgesic drug products covered pursuant to this section shall not exceed the lowest cost-sharing level applied to generic non-abuse deterrent opioid drugs covered under the applicable health plan or policy.
(3) An increase in patient cost-sharing or disincentives for prescribers or dispensers shall not be allowed to achieve compliance with this section.
(b) Any prior-authorization requirements or other utilization review measures for opioid analgesics, and any service denials made pursuant thereto, shall not require use of opioid analgesic drug products without abuse-deterrent properties in order to access abuse-deterrent opioid analgesic drug products.
(c) Definitions. As used in this section:
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD06749-01-1
S. 6180 2
(1) "Opioid analgesic drug product" means a drug in the opioid analgesic drug class prescribed to treat moderate to severe pain or other conditions, whether in immediate release or extended long acting release form and whether or not combined with other drug substances to form a single drug product or other dosage form.
(2) "Abuse deterrent opioid analgesic drug product" means a brand or generic opioid analgesic drug product approved by the federal food and drug administration with abuse-deterrence labeling claims indicating its abuse-deterrent properties are expected to deter or reduce its abuse.
(3) "Cost-sharing" means any coverage limit, copayment, coinsurance, deductible or other out-of-pocket patient expense requirements.
§ 2. This act shall take effect on the one hundred twentieth day after it shall have become a law, and shall apply to all policies and contracts issued, renewed, modified, altered or amended on or after such date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the insurance law, in relation to the use of abuse-det- errent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs
Purpose or general idea of bill
To help prevent the abuse and diversion of opioid analgesic drugs by ensuring that abuse-deterrent drugs approved by the FDA are accessible to patients and that that insurance coverage does not disadvantage access for patients to drugs approved by the FDA as abuse-deterrent.
Summary of specific provisions
Section 1 adds a new section 3216-a to the insurance law to ensure patient access to abuse-deterrent opioid analgesic drugs by requiring that a minimum of one opioid abuse-deterrent opioid analgesic drug per opioid analgesic active ingredient is covered by insurance plans and to ensure that a patient is not required to take a non-abuse deterrent opioid before an abuse-deterrent opioid version.
Read the full memo (629 words)
Section 2 is the effective date of the bill.
Justification
While pain management is an important and integral part of the health care system, abuse and diversion of opioids has necessitated the imple- mentation of various anti-abuse policies. These policies need to be approached comprehensively by government, law enforcement, health care providers and manufacturers and an important component is to ensure that opioids incorporating abuse-deterrent technologies are dispensed whenev- er possible.
The U.S. Food and Drug Administration (FDA) has recognized that the development and implementation of abuse-deterrent technologies is an important "step towards the goal of creating safer opioid analgesics." In recently published FDA guidance on abuse-deterrent technologies for opioids, the FDA provided that they "consider the development of these products a high public health-priority." To combat opioid misuse and abuse, the FDA is encouraging manufacturers to develop abuse-deterrent formulations that when taken as prescribed still provide appropriate pain relief, but are-formulated to make it more difficult to alter the drug product for purposes of misuse or abuse, such as making the product harder to crush or liquefy in order to snort or inject. The FDA has provided guidance as to the steps that a manufacturer can take to demon- strate that an opioid drug product is formulated with abuse-deterrent technologies and after rigorous testing has shown that the abuse-deter- rent formulation is expected to deter or reduce abuse of the drug prod- uct. It is only after achieving successful results on these tests that the FDA will allow for a drug product's label to include claims based on demonstration of meaningful abuse-deterrent properties.
This proposal recognizes that to further the goal of encouraging the use of abuse-deterrent technologies as part of a broader plan to reduce opioid addiction and abuse, it is imperative that insurance coverage is applied equitably and does not provide a disincentive to the use of abuse-deterrent opioids. This will help advance safe patient care by ensuring that abuse-deterrent versions of available opioid analgesic drug products are covered, including those containing nonopioid drug substances to form a single drug product.
While New York State has been at the forefront of fighting prescription drug abuse, it is critical that the State continue to strengthen its laws and protect against abuse while enhancing the integrity of its health care system. Enacting this proposal will be consistent with these goals and with the priorities set out by the FDA.
Prior legislative history
2020: S.3272 Referred to Insurance
2019: S.3272 - Referred to Insurance
2018: S.7009 Referred to Insurance / A.7999 - Referred to Insurance
2017: A.7999 - Referred to Insurance
Fiscal implications
None.
Effective date
This act shall take effect on the 120th day, and shall apply to all policies and contracts issued, renewed, modified, altered or amended on NEW YORK STATE SENATE INTRODUCER'S MEMORANDUM IN SUPPORT submitted in accordance with Senate Rule VI. Sec 1
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.